Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.
Type:
Grant
Filed:
August 19, 2013
Date of Patent:
July 14, 2015
Assignee:
Invion Limited
Inventors:
Dean Jason Taylor, Barbara Jane Johnson, Caroline Amanda Dobbin, Christopher Bruce Howard, Linda Allison Ward
Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.
Type:
Application
Filed:
August 19, 2013
Publication date:
April 3, 2014
Applicant:
INVION Limited
Inventors:
Dean Jason TAYLOR, Barbara Jane JOHNSON, Caroline Amanda Dobbin, Christopher Bruce HOWARD, Linda Allison WARD
Abstract: The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.
Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.
Type:
Grant
Filed:
June 7, 2011
Date of Patent:
August 20, 2013
Assignee:
Invion Limited
Inventors:
Dean Jason Naylor, Barbara Jane Johnson, Caroline Amanda Dobbin, Christopher Bruce Howard, Linda Allison Ward